Research programme: bispecific antibody therapeutics - Amgen/Bayer

Drug Profile

Research programme: bispecific antibody therapeutics - Amgen/Bayer

Alternative Names: CD33 BiTE antibody; EGFR BiTE antibody; HER2 BiTE antibody; MCSP BiTE antibody

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
  • 26 Apr 2012 Amgen and Bayer HealthCare Pharmaceuticals expand their collaborative agreement to include the development and commercialisation of a second BiTE® antibody for the treatment of Solid tumours
  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top